The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
The 20th edition of BioAsia organised by the Government of Telangana, will feature prominent government dignitaries, industry leaders, researchers, entrepreneurs, and other delegates, and explore the theme of Advancing for ONE: Shaping the next generation of humanised healthcare. The event is scheduled to be held between February 24 and 26, 2023 at the Hyderabad International Convention Center (HICC) in Hyderabad. Ernst and Young will be the knowledge partner of the event.
Participants include
- Dr Vas (Vasanth) Narasimhan, CEO, Novartis, Switzerland
- Prof Robert Langer, Prof at MIT And Co-Founder, Moderna, USA (A scientist, entrepreneur, professor at MIT and co-founder Moderna Therapeutics with 37 honorary doctorates. He has been awarded the US National Medal of Science, US National Medal of Technology and Innovation, Queen Elizabeth Prize for Engineering. Max Planck Research Award, among others. He has also been named as one of the 25 most important individuals in biotechnology in the world by Forbes and by Time Magazine and CNN as one of the 100 most important people in US.)
- Dr Richard Hatchett, CEO, CEPI
- Dr Rahul Singhvi, CEO, Resilience, USA
- Dr Mark Abdoo, Associate Commissioner for Global Policy and Strategy, US-FDA
- Dr Gregory Moore, Vice President of Corporate Planning at Microsoft, USA
- Prof Sarfaraz K Niazi, Adj Professor of Pharmaceutical Sciences, University of Illinois, Chicago, USA
- Dr Samit Hirawat, Executive Vice President and Chief Medical Officer for the Global Drug Development division, Bristol-Myers Squibb, USA;
- Dr Sarah Mcmullen, Country Director – India, FDA
- Dr Soumya Swaminathan, Chief Scientist, World Health OrgaOrganization
- Dr Shyam Bishen, Executive Director for Shaping the Future of Health and Healthcare, World Economic Forum, Switzerland
- Agam Upadhyay, SVP, Chief Technology Officer, GSK, USA
- Pavan Kumar Mocherla, MD India And South Asia, BD, Singapore
Other distinguished speakers are Dr Sangita Reddy, Joint MD, Apollo Hospitals (India); Satish Reddy, Chairman, Dr Reddy’s Laboratories; Dr Gagandeep Kang, Virologist, and Professor, Dept of Gastrointestinal Sciences, CMC Vellore, Dr S Chandrasekhar, Secretary to the Government of India, Department of Science & Technology, Glenn Saldanha, CMD, Glenmark Pharmaceuticals, Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines, Dr Rehan Khan, MD, MSD India, Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMED), Dr Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures, etc.
KT Rama Rao, Minister of IT E&C, MA&UD and Industries & Commerce Departments, Government of Telangana said, “Telangana has been playing a significant role in strengthening the positioning of the country in the worldwide life sciences industry. Several key global players have been leveraging the ecosystem provided by the state by setting up their operations in the state. BioAsia has created a legacy by providing a platform for global leaders to deliberate on healthcare’s key requirements over the last 20 years. I am confident that the world will continue to hear and learn from the brilliant minds at the conference.”
“BioAsia has played an instrumental role in the development of the Healthcare Industry around the world. Over the last 20 years, BioAsia has hosted over 20,000 B2B, B2R, and R2R meetings that led to strategic business deals, making Telangana the life sciences capital of the world. 250+ Lols, Bilateral Cooperation agreements, and MoUs were signed and 30+ knowledge papers and policy recommendations were also implemented. This 20th edition is likely to contribute to a significant amount of collaboration among all the key stakeholders for the development of the healthcare industry,” said Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana.
“With a prominent speaker line-up from the healthcare industry, we are confident that this edition will help in bridging the gaps in the healthcare industry. Over the years, BioAsia has emerged as one of the key contributors to the development of the life sciences industry. The conference will deliberate on some of the most relevant aspects of the life sciences/healthcare industry including the potential strategies for operationalising the one health approach, building more resilient supply chains in light of the current geopolitical trends, opportunities for the Indian medtech industry and the issues plaguing the growth, role of technologies like AI, ML metaverse in healthcare, regulatory and government support required to accelerate growth and make innovative therapies available to patients at affordable cost, adopting ESG as a culture, among others,” said Shakthi Nagappan, Director of Life Sciences, Government of Telangana and CEO, BioAsia.
“The cross-sectoral collaborations will bring major think tanks together at BioAsia2023 in inducing critical deliberations from the Lifesciences industry to ensure a more inclusive approach. The pandemic has made us learn an important aspect that a collective effort can assist in coping with a larger issue rather than tackling it in silos. BioAsia 2023’s theme “Advancing for one” would further augment this collaborative effort and help the industry to be better equipped for any future challenges. We at EY are delighted to be facilitating this vision as BioAsia2023’s knowledge partners,” commented Suresh Subramanian, Partner, National Life Sciences Leader at EY India.
